Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251643 | 0.83 | SMN1; SMN2 (0.31) | ALDH1A1EPHX2SCN4ASMN1; SMN2 | |
| SCHEMBL20791827 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDSMN1; SMN2LMNAPDE10A | |
| SCHEMBL25263416 | 0.77 | FBP1 (0.34) | ALDH1A1EPHX2HPGD | |
| SCHEMBL8806645 | 0.76 | MEN1 (0.39) | — | |
| SCHEMBL1897569 | 0.76 | ALDH1A1 (0.39) | ALDH1A1EPHX2SCN4AHPGDHSD17B10 | |
| SCHEMBL2145717 | 0.74 | CNR2 (0.30) | — | |
| SCHEMBL20907837 | 0.74 | MPL (0.42) | ALDH1A1EPHX2SCN4AHPGDHSD17B10 | |
| SCHEMBL3067173 | 0.74 | ENPP3 (0.33) | — | |
| SCHEMBL23214563 | 0.74 | ALDH1A1 (0.37) | ALDH1A1HPGDSMN1; SMN2NOS1 | |
| SCHEMBL2307680 | 0.73 | ALDH1A1 (0.37) | ALDH1A1EPHX2SCN4AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| WO-2018134731-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-26 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9670192-B2 | Substituted isoxazole derivatives | BASF SE (DE) | 2017-06-06 | — | — | US | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2004056177-A2 | INSECTICIDAL AMINOTHIAZOLE DERIVATIVES | NIPPON SODA CO. LTD. (JP) | 2004-07-08 | — | — | WO | disclosed |
| US-6737382-B1 | WIDE SPECTRUM OF PLANT PROTECTING ACTIVITY | NIPPON SODA CO. LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20040082629-A1 | INSECTICIDAL AMINOTHIAZOLE DERIVATIVES | NIPPON SODA CO., LTD. | 2004-04-29 | — | — | US | disclosed |
| US-5605912-A | INSECTICIDES, MITICIDES | ROUSSEL UCLAF (FR) | 1997-02-25 | — | — | US | disclosed |
| EP-0547972-B1 | Heterocyclic amide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-03-22 | — | — | EP | disclosed |
| US-5380733-A | Certain pyridyl-5-phenyl-1-cyclopropyl-dienamide pesticides | ROUSSEL UCLAF (FR) | 1995-01-10 | — | — | US | disclosed |
| CN-1076190-A | Sterilant | ROUSSEL UCLAF (FR) | 1993-09-15 | — | — | CN | disclosed |
| EP-0547972-A1 | Heterocyclic amide derivatives and their use as pesticides | ROUSSEL-UCLAF (FR) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082629-A1 | INSECTICIDAL AMINOTHIAZOLE DERIVATIVES | SCN7A, SCN2B, CASP7 | ALDH1A1 1229/4885EPHX2 2621/4885SCN4A 5/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | ALDH1A1 4695/4885EPHX2 1907/4885SCN4A 4094/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | ALDH1A1 4730/4885EPHX2 2319/4885SCN4A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.